NDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
TORADOL (ketorolac tromethamine) by Roche is clinical pharmacology pharmacodynamics ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits analgesic activity in animal models. First approved in 1991.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORADOL (ketorolac tromethamine) is a potent nonsteroidal anti-inflammatory drug (NSAID) administered orally, intramuscularly, or intravenously for moderate to severe acute pain management. It works by inhibiting prostaglandin synthetase, delivering peak analgesic effects within 2-3 hours with duration varying by dose strength. The drug is indicated for short-term pain relief in post-operative and acute care settings.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand teams should focus on lifecycle extension and generic transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin…
Worked on TORADOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.